KESHAVARZ-SHOKRI ALI,NUMA MEHDI,ALCACIO TIM EDWARD,KRAWIEC MARIUSZ,KAUSHIK RITU ROHIT,ZAMAN NOREEN TASNEEM,BINCH HAYLEY MARIE,YOUNG CHRISTOPHER RYAN,FANNING LEV TYLER DEWEY,ZHANG YUEGANG,ZLOKARNIK GRE
申请号：
NZ60304411
公开号：
NZ603044A
申请日:
2011.04.22
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is a pharmaceutical composition comprising one of the following combinations: a) Compound 1 and Compound 2 Form I b) Compound 1 Form A and Compound 2 Form I c) Compound 1 Form A and Compound 2 Tablet Formulation d) Compound 1 Form A-HCl and Compound 2 Form I e) Compound 1 Form B-HCl and Compound 2 Form I f) Compound 1 Form B, and Compound 2 Form I g) Compound 1 Form A-HCl and Compound 2 Tablet Formulation h) Compound 1 Form B-HCl and Compound 2 Tablet Formulation and i) Compound 1 Form B, and Compound 2 Tablet Formulation, wherein Compound 1 is N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide Compound 2 is lumacaftor (VX-809 / 3-{ 6-{ [1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino} -3-methylpyridin-2-yl} benzoic acid) Compound 1 Form A is characterized by a peak at about 7.9 degrees and a peak at about 11.9 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation Compound 1 Form A-HCl is characterized by a peak at about 7.1 degrees, a peak at about 8.2 degrees, a peak at about 14.1 degrees, and a peak at about 21.2 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation Compound 1 Form B-HCl is characterized by a peak at about 8.3 degrees, a peak at about 9.0 degrees, a peak at about 13.0 degrees, a peak at about 18.0 degrees, and a peak at about 23.0 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation Compound 1 Form B is characterized by a peak at about 6.7 degrees, a peak at about 10.0 degrees, a peak at about 11.2 degrees, a peak at about 13.4 degrees, a peak at about 24.2 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation Compound 2 Form I is characterized by the following peaks in an X-ray powder diffraction obtained using Cu K alpha radiation: a peak at 15.4 degrees, a peak at 16.3 degrees, and a peak at 14.5 degrees and Compound 2 Tablet Formulation comprises: a. Compound
